Ying Zhang
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
Rubbert-Roth A, Enejosa J, Pangan A, Haraoui B, Rischmueller M, Khan N, Zhang Y, Martin N, Xavier R. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med 2020; 383:1511-1521.
15.01.2020Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
15.01.2020N Engl J Med 2020; 383:1511-1521
Rubbert-Roth Andrea, Enejosa Jeffrey, Pangan Aileen L, Haraoui Boulos, Rischmueller Maureen, Khan Nasser, Zhang Ying, Martin Naomi, Xavier Ricardo M
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Genovese M, Meerwein S, Mohamed M, Zhou Y, Zhang Y, Rubbert-Roth A, Hall S, Combe B, Fleischmann R, Pangan A. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 2018; 391:2513-2524.
18.06.2018Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
18.06.2018Lancet 2018; 391:2513-2524
Genovese Mark C, Meerwein Sebastian, Mohamed Mohamed-Eslam F, Zhou Yijie, Zhang Ying, Rubbert-Roth Andrea, Hall Stephen, Combe Bernard, Fleischmann Roy, Pangan Aileen L